Vivek Ramaswamy, a lesser-known billionaire compared to Elon Musk, is one of two individuals selected by President-elect Donald J. Trump to lead an initiative aimed at reducing government expenses.

Ramaswamy Has a High-Profile Perch and a Raft of Potential Conflicts

Elon Musk, Ramaswamy’s more prominent counterpart, stands to gain significantly from the position due to his companies’ extensive government contracts and influence, as well as ongoing interactions with federal regulators. Meanwhile, Ramaswamy’s intricate financial interests, spanning biotechnology, finance, and other sectors, have drawn less scrutiny, though they may pose significant conflicts of interest.https://wordpress.com/

At 39, Ramaswamy is among the youngest billionaires globally, having amassed his wealth in the pharmaceutical industry. His involvement in government restructuring could lead to budget cuts that benefit him and his investors financially. He holds a nearly $600 million stake in a biotechnology company he founded and has advocated for reforms at the Food and Drug Administration (FDA) to expedite drug approvals. Additionally, his investment firm’s oil-and-gas fund, provocatively named DRLL, could see advantages if energy policies favor fossil fuels. Similarly, his firm’s Bitcoin initiatives could benefit from pro-cryptocurrency policies.

It remains unclear whether leaders of the Department of Government Efficiency (DOGE)—a non-governmental advisory organization—will face the same divestment requirements as federal appointees. Ramaswamy, who stepped away from managing his businesses two years ago, has not disclosed whether he plans to divest from his holdings, including his majority ownership in Strive Enterprises, an investment firm he branded as a counter to liberal agendas. Strive’s financial backers include individuals with ties to the incoming Trump administration.

Since his appointment, Ramaswamy has used Elon Musk’s social media platform, X, to outline his plans, including reducing regulations and targeting diversity-focused federal workers for layoffs. He has also criticized the FDA’s requirements for drug approval, calling for streamlined processes.

Ramaswamy’s biotech venture, Roivant Sciences, gained fame for both successes and failures. In 2015, its Alzheimer’s drug Axovant attracted significant investment but failed in trials, wiping out over $1.3 billion in stock value. Despite this, Ramaswamy navigated the setback, with Roivant now valued at $8 billion and having secured FDA approvals for six products. His stake in Roivant remains substantial, and any regulatory changes under DOGE that accelerate drug approvals could enhance the company’s value.

Ramaswamy has also been a vocal critic of the Environmental, Social, and Governance (ESG) movement. He co-founded Strive Enterprises with Anson Frericks to appeal to investors disenchanted with ESG policies. Their first offering, DRLL, an exchange-traded fund (ETF) focused on energy companies, aims to pressure firms to reject liberal policies. Although the fund mirrors existing ETFs, Ramaswamy positions it as part of a broader campaign to influence corporate governance.

Strive’s strategy includes engaging directly with energy companies like Chevron and Exxon, urging them to move away from climate-focused policies. Ramaswamy’s involvement in these efforts coincides with his growing political ambitions, as he continues to navigate the intersections of business, policy, and public service.